BRCA2 and triple-negative breast carcinoma: To test whether targeting mTOR and DNA repair could be a relevant therapeutic strategy in triple-negative breast cancer, we tested the combination of everolimus and olaparib in PDX model established from a BRCA2-mutated basal-like breast cancer [19].